Trial Design

INSIGHTS ON CLINICAL TRIAL DESIGN

What Everest Group's RTSM Recognition Means For The Industry
RTSM is transforming from a basic operational tool into a strategic driver of trial efficiency. Learn why industry recognition signals a new era of innovation and competitive advantage.
Rethinking Trial Access Through Trust-Driven Design And Local Collaboration
Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.
5 Questions To Ask Before Selecting A Randomization Partner
Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.
Simultaneous Submissions And Managing Multiple Regulatory Pathways
Global regulators are increasingly aligned, creating new opportunities for sponsors to pursue near-simultaneous submissions across major markets

Configuration Over Code: Why RTSM Architecture Matters Long After Go-Live
8/1/2026

Learn how configuration-driven RTSM architecture can simplify protocol changes, reduce operational burden, and help teams manage amendments with greater efficiency and control.
Critical Imaging Risks In GLP-1 And Neurology Studies
5/27/2025

As imaging grows in importance within GLP-1 and neurology trials, it must be treated not as a routine task but as a strategic pillar that supports participant safety and reproducible outcomes.
The Path Forward In Oncology Trials
9/10/2025

A comprehensive site support model is crucial for navigating the complexities of modern oncology trials and accelerating drug development.
Rewriting The Code: Advances And Challenges In Pediatric Gene Therapy
7/28/2026

This presentation examines pediatric gene therapy and the three platforms now driving clinical progress: AAV vectors, lentiviral vectors, and CRISPR-based gene editing.
How Adaptive Design Accelerates Early‑Phase NSCLC Development
5/22/2026

Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

De-Risk Randomization With The Endpoint Biostatistical Approach

With over 15 years of RTSM experience, high-touch quality management, and forward-thinking technology, our solutions enhance trial speed, accuracy, and operational efficiency.
TrialScope Disclose

With TrialScope Disclose, study sponsors streamline and optimize the entire clinical trial disclosure process from initial registration to final results — mitigating risk, maximizing transparency and ultimately moving healthcare forward.
Flexible And Simplified Consent Management

Learn about a unified ecosystem integrating eConsent, IRT, eCOA, and ePatient into a seamless workstream designed with a patient-centric approach.
Endocrine & Metabolic Expertise To Enable Your Success

Veristat has built a team of scientific-minded experts who have supported more than 300 projects for endocrine/metabolic disorder treatments and prepared over 30 marketing applications, 60% of which have been approved or authorized to date.
A Data-Driven And Transparent Approach To Vaccine Research

Looking for faster trial startup, diverse participant pools, and consistent site quality? Explore a vaccine research network designed to keep your study on time and on target.